417 related articles for article (PubMed ID: 32987786)
1. Pancreatic Ductal Adenocarcinoma (PDAC) Organoids: The Shining Light at the End of the Tunnel for Drug Response Prediction and Personalized Medicine.
Frappart PO; Hofmann TG
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 32987786
[TBL] [Abstract][Full Text] [Related]
2. Establishment of organoid models for pancreatic ductal adenocarcinoma and screening of individualized therapy strategy.
Gong M; Meng H; Tan D; Li P; Qin J; An Q; Shi C; An J
Animal Model Exp Med; 2023 Oct; 6(5):409-418. PubMed ID: 37890865
[TBL] [Abstract][Full Text] [Related]
3. State of the art and future directions of pancreatic ductal adenocarcinoma therapy.
Neuzillet C; Tijeras-Raballand A; Bourget P; Cros J; Couvelard A; Sauvanet A; Vullierme MP; Tournigand C; Hammel P
Pharmacol Ther; 2015 Nov; 155():80-104. PubMed ID: 26299994
[TBL] [Abstract][Full Text] [Related]
4. Microfluidic Platforms for High-Throughput Pancreatic Ductal Adenocarcinoma Organoid Culture and Drug Screening.
Geyer M; Queiroz K
Front Cell Dev Biol; 2021; 9():761807. PubMed ID: 35004672
[TBL] [Abstract][Full Text] [Related]
5. OrganoIDNet: a deep learning tool for identification of therapeutic effects in PDAC organoid-PBMC co-cultures from time-resolved imaging data.
Ferreira N; Kulkarni A; Agorku D; Midelashvili T; Hardt O; Legler TJ; Ströbel P; Conradi LC; Alves F; Ramos-Gomes F; Markus MA
Cell Oncol (Dordr); 2024 May; ():. PubMed ID: 38805131
[TBL] [Abstract][Full Text] [Related]
6. Modeling human pancreatic ductal adenocarcinoma for translational research: current options, challenges, and prospective directions.
Suri R; Zimmerman JW; Burkhart RA
Ann Pancreat Cancer; 2020 Dec; 3():. PubMed ID: 33889840
[TBL] [Abstract][Full Text] [Related]
7. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
8. Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma.
Al Haddad AH; Adrian TE
Expert Opin Investig Drugs; 2014 Nov; 23(11):1499-515. PubMed ID: 25078674
[TBL] [Abstract][Full Text] [Related]
9. A pancreas tumor derived organoid study: from drug screen to precision medicine.
Yao J; Yang M; Atteh L; Liu P; Mao Y; Meng W; Li X
Cancer Cell Int; 2021 Jul; 21(1):398. PubMed ID: 34315500
[TBL] [Abstract][Full Text] [Related]
10. In-vitro model to mimic T cell subset change in human PDAC organoid co-culture.
Knoblauch M; Ma T; Beirith I; Koch D; Hofmann F; Heinrich K; Aghamaliev U; Sirtl S; Westphalen CB; Nieß H; Reichert M; Angele MK; Regel I; Bazhin AV; Werner J; Ilmer M; Renz BW
J Cancer Res Clin Oncol; 2023 Nov; 149(14):13051-13064. PubMed ID: 37470855
[TBL] [Abstract][Full Text] [Related]
11. Update on the management of pancreatic cancer: surgery is not enough.
Ansari D; Gustafsson A; Andersson R
World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920
[TBL] [Abstract][Full Text] [Related]
12. Pancreas 3D Organoids: Current and Future Aspects as a Research Platform for Personalized Medicine in Pancreatic Cancer.
Moreira L; Bakir B; Chatterji P; Dantes Z; Reichert M; Rustgi AK
Cell Mol Gastroenterol Hepatol; 2018 Mar; 5(3):289-298. PubMed ID: 29541683
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic Cancer Organoids in the Field of Precision Medicine: A Review of Literature and Experience on Drug Sensitivity Testing with Multiple Readouts and Synergy Scoring.
Mäkinen L; Vähä-Koskela M; Juusola M; Mustonen H; Wennerberg K; Hagström J; Puolakkainen P; Seppänen H
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158794
[TBL] [Abstract][Full Text] [Related]
14. Metabolic Profiling of Early and Late Recurrent Pancreatic Ductal Adenocarcinoma Using Patient-Derived Organoid Cultures.
Braun LM; Lagies S; Klar RFU; Hussung S; Fritsch RM; Kammerer B; Wittel UA
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32492856
[TBL] [Abstract][Full Text] [Related]
15. New challenges in perioperative management of pancreatic cancer.
Puleo F; Maréchal R; Demetter P; Bali MA; Calomme A; Closset J; Bachet JB; Deviere J; Van Laethem JL
World J Gastroenterol; 2015 Feb; 21(8):2281-93. PubMed ID: 25741134
[TBL] [Abstract][Full Text] [Related]
16. Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer.
Chiang NJ; Chang JY; Shan YS; Chen LT
Expert Opin Pharmacother; 2016 Jul; 17(10):1413-20. PubMed ID: 27140876
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies.
Chiaravalli M; Reni M; O'Reilly EM
Cancer Treat Rev; 2017 Nov; 60():32-43. PubMed ID: 28869888
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic Cancer Organoids: An Emerging Platform for Precision Medicine?
Sereti E; Papapostolou I; Dimas K
Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979869
[TBL] [Abstract][Full Text] [Related]
19. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe.
Javed MA; Beyer G; Le N; Vinci A; Wong H; Palmer D; Morgan RD; Lamarca A; Hubner RA; Valle JW; Alam S; Chowdhury S; Ma YT; Archibugi L; Capurso G; Maisonneuve P; Neesse A; Sund M; Schober M; Krug S
Pancreatology; 2019 Jan; 19(1):97-104. PubMed ID: 30529068
[TBL] [Abstract][Full Text] [Related]
20. Advanced Pancreatic Ductal Adenocarcinoma: Moving Forward.
Franck C; Müller C; Rosania R; Croner RS; Pech M; Venerito M
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
